Ergoteles’s iBio IBIO Stock Holding History

Ergoteles’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,671	Closed	-$142K	–	1652
2022 Q3	$142K	Sell	1,671 -387	-19%	-$53.3K	0.01%	1291
2022 Q2	$272K	Buy	+2,058	New	+$309K	0.01%	1158
2021 Q3	–	Sell	-71	Closed	-$54K	–	1417
2021 Q2	$54K	Buy	+71	New	+$51.8K	﹤0.01%	1441

Other funds holding IBIO

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Ergoteles's IBIO Position: Q4 2022 in Review

Ergoteles sold out of iBio (IBIO) in Q4 2022, closing a stake of 1,671 shares — an estimated $142K sold.

Ergoteles first reported a position in IBIO in Q2 2021 and held it in 3 quarters. The position peaked at $272K in Q2 2022. 36 funds tracked by Wall St. Rank hold IBIO as of Q4 2022.

Ergoteles reported no remaining iBio position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 1,671 iBio shares in Q4 2022, an estimated $142K.
Ergoteles first reported a position in iBio in Q2 2021 and held it in 3 quarters.
Ergoteles's iBio position peaked at $272K in Q2 2022.
36 funds tracked by Wall St. Rank held iBio as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.